Mitosyl, Silomat … Sanofi sells 16 consumer health brands to German Stada

French drug maker Sanofi on Monday (June 28th) announced the sale of 16 brands of consumer health products, mostly European, to German private equity firm Stada in order to streamline its product portfolio. Stada said in a statement that the purchase of these brands, including Mitosyl ointment, Silomat cough remedies and Frubiase dietary supplements, will strengthen its regional sales network in Europe, following a similar deal with GlaxoSmithKline in 2020.

Transaction between 120 and 140 million euros

The companies were unwilling to disclose financial terms, but someone familiar with the matter said the price was in a range of 120 million to 140 million euros. Sanofi has said it will prioritize fast-growing consumer health brands as the consumer division prepares to become a stand-alone business.



logo indice & contations

“As we reported at our February Capital Markets Day, simplifying the consumer health product portfolio is an important aspect of our strategy to focus our resources and efforts where we can deliver the most value. , especially for consumers, “said June 28 Julie Van Ongevalle, head of the general public health unit of Sanofi, in a statement.

Cash flow after several investments

This sale comes after a wave of investments from the French laboratory. In March 2021, Sanofi had committed 600 million euros to Canada for the production of its influenza vaccine. The following month, the French again committed 400 million euros, in Singapore this time to set up a digital vaccine factory.

With Reuters, report by Ludwig Burger, French version Hayat Gazzane, edited by Blandine Hénault